ANTIBODY-BASED DIAGNOSTIC FOR PERIODONTAL DISEASE

基于抗体的牙周疾病诊断

• 批准号: 2535927
• 负责人: MARTIN LEVINE
• 金额: $ 9.83万
• 依托单位: BIO-MEDICAL SERVICES, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-03-01 至 1999-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2535927
• 关键词: Actinomyces; antibacterial antibody; antibody; antibody titering; dental disorder diagnosis; diagnosis design /evaluation; diagnostic tests; immunologic assay /test; oral bacteria; periodontium disorder

DESCRIPTION: (Adapted from investigator's Abstract) Some patients cannot control tooth attachment loss (periodontitis) after intensive oral hygiene therapy. Recently, successful therapy was found to depend on an increased prevalence of "beneficial" relative to "pathogenic" bacteria in gingival sulci. A simple procedure based on this finding is proposed: an enzyme immunoassay to measure the concentration of specific for Actinomyces spp. (A-Ab), a major component of the beneficial flora. The specific aim of this Phase 1 proposal is to compare the A-Ab concentration in patients who are either refractory or responsive to therapy. High and low A-Ab concentrations will be separated by a cutoff value derived from antigen/antibody precipitation and enzyme immunoassay. Near this value, the determination of high/low A-Ab response requires measuring a control antibody, to unstable D- alanyl esters of lipoteichoic acid from streptococci (S-Ab). The Phase 2 aims are to determine: (1) whether therapy alters A-Ab concentration in longitudinal studies; (2) whether A-Ab concentration affects treatment needs; and (3) whether S-Ab content can be measured with stable surrogate antigens. The proposed assay should identify refractory patients faster and more accurately than clinical skills, or assays for pathogenic bacteria or host-produced destructive enzymes at gingival sulci. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述：（改编自研究者摘要）一些患者 强化治疗后不能控制牙齿附着丧失（牙周炎） 口腔卫生治疗 最近，成功的治疗被发现依赖于 “有益”相对于“致病”的流行率增加 龈沟中的细菌。 基于这一发现的一个简单程序 提出了一种酶免疫测定法， 放线菌属特异性（A-Ab），其主要组分 有益植物群。 第一阶段提案的具体目标是 比较难治性患者或 对治疗有反应 高和低A-Ab浓度将 通过来自抗原/抗体沉淀的临界值分离 和酶免疫测定。 在该值附近，高/低的确定 A-Ab应答需要测量对照抗体，以检测不稳定的D- 来自链球菌的脂磷壁酸的丙氨酰酯（S-Ab）。 相位 2个目的是确定：（1）治疗是否改变A-Ab浓度 在纵向研究中;（2）A-Ab浓度是否影响 治疗需要;（3）是否可以用 稳定的替代抗原。 拟定的试验应鉴别 难治性患者比临床技能更快、更准确，或 病原菌或宿主产生的破坏性酶的测定. 龈沟 拟议商业应用：不可用

项目成果

Antibody-based diagnostic for 'refractory' periodontitis.

基于抗体的“难治性”牙周炎诊断。

• DOI: 10.1034/j.1600-051x.2002.291009.x
• 发表时间: 2002
• 期刊: Journal of clinical periodontology
• 影响因子: 6.7
• 作者: Levine,M;LaPolla,S;Owen,WL;Socransky,SS
• 通讯作者: Socransky,SS